Mogadon (Nitrazepam)

Nitrazepam enhances the activity of the neurotransmitter GABA at the GABAA receptor. By acting as a positive allosteric modulator, it increases chloride ion flow into neurons, producing a calming effect that reduces neuronal excitability, leading to sedation, hypnosis, and anxiolysis.

The appropriate dose of Mogadon is determined individually by a qualified prescriber based on the patient’s condition, age, response, and any concomitant therapies. Healthcare professionals will select the strength and dosing schedule that best fits the therapeutic goal.

Safety data for nitrazepam in pregnancy and lactation are limited. The prescriber should weigh potential benefits against possible risks to the fetus or infant. Generally, use is avoided unless clearly needed, and alternative treatments may be considered.

To request Mogadon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any required import documentation.

Mogadon (nitrazepam) is a long‑acting benzodiazepine, offering a prolonged hypnotic effect useful for sleep maintenance. Compared with shorter‑acting agents such as temazepam, nitrazepam may have a higher risk of next‑day sedation but can be advantageous for patients needing sustained sleep support.

Mogadon tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Mogadon is taken orally as a tablet. The tablet should be swallowed whole with a glass of water, preferably at bedtime for insomnia or as directed by the prescriber for anxiety. Do not crush, chew, or split the tablet unless advised.

The most serious risks include the development of physical dependence and withdrawal syndrome, severe respiratory depression especially when combined with other depressants, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for these events.

Mogadon is contraindicated in individuals with known hypersensitivity to nitrazepam or other benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, and in patients with severe hepatic impairment. It should also be avoided in anyone taking potent CNS depressants without medical supervision.